Antibiotic in Medical Technology

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... profile sets it apart from other antibiotic formulations (including free tobramycin). ... which, by allowing effective penetration of the antibiotic into the bacterial cell, completely changes the ... could be a totally new antibiotic formulation that addresses microbiological needs ...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

... (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections ... is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules ... The company's major focus is on developing antibiotic therapy delivered via proprietary advanced ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... of oral torezolid (TR-701), its investigational antibiotic for the treatment of severe complicated skin and ... that patients had a clear need for systemic antibiotic therapy," said Philippe Prokocimer, M.D., Chief ... is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, ...

CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients

... Physicians are also concerned about emerging antibiotic resistance in this population, with 96 percent of ... control for cancer patients and appropriate antibiotic management to prevent resistance. It will also ... improve infection control and promote appropriate antibiotic stewardship for these high-risk patients," says ...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

... Against Anaerobes is the Leading Attribute in antibiotic Selection, According to a New Report from AMR and ... against anaerobes as the leading attribute in antibiotic selection. Intra-abdominal infections are often ... carbapenems, address some of these attributes, no antibiotic captures all of the top most important attributes ...

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

... a clinical recurrence following cessation of antibiotic administration. Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging ... formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical ...

AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe

... Faster Results to Help Clinicians Improve antibiotic Selection and Outcomes for Critical Infections ... bloodstream pathogens to help clinicians optimize antibiotic therapy and improve care for patients with ... results by up to 48-72 hours, improved antibiotic selection for patients with bloodstream ...

Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity

... of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal ... "There is a need for a safe and efficacious antibiotic to treat pseudomonal infections. Unfortunately, ... many strains resistant to carbapenems, an antibiotic class generally considered as having the most ...

Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds

... 2008-09 are autism spectrum disorders (ASD) and antibiotic resistance. Each grant is required to establish a ... can be effectively controlled using existing antibiotic drugs, there has been a significant increase in antibiotic drug resistance rates in health care institutions ...

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin

... Compound Demonstrates Potent Activity Against antibiotic Resistant Gram-Positive Pathogens and MRSA in ... delafloxacin for the over $9.9 billion hospital antibiotic market. (1) Delafloxacin cSSSI ... synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative ...

Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome

... against the approval of intravenous iclaprim, an antibiotic currently in development for the treatment of ... About Iclaprim Iclaprim is an antibiotic currently in development for the treatment ... to combat resistant infections and is the first antibiotic in the dihydrofolate reductase (DHFR) selective ...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

... days post-therapy. After at least 4 days of IV antibiotic therapy, patients may be switched to ... protocol-defined criteria. The total duration of antibiotic therapy for each patient should be 7 to 14 days. ... products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in ...

Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD

... in the clinical community for an inhaled antibiotic that can reduce the incidence of acute ... new therapies to combat the growing issue of antibiotic resistance. The company's internal development ... molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's most advanced product ...

Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207

... included synergy studies, rate of killing, post antibiotic effect and intracellular activity against MTB in ... showed increased rate of killing, enhanced post antibiotic effect and intracellular killing activity. ... Phase I clinical trials, is a new diamine antibiotic that could replace one or more of the current ...

New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria

... for injection) DORIBAX is an intravenous (IV) antibiotic for hospital use, and belongs to a class of ... all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since ... If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to ...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

... on 20 November 2008. Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) ... medical procedure.(iii,iv) The most common antibiotic used to treat MRSA infections is vancomycin, but ... States.(ix) About Iclaprim Iclaprim is an antibiotic currently in development for the treatment ...

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... PTK 0796 is that it is the first broad-spectrum antibiotic with activity against MRSA that will have the ... the pipeline of replacement products that target antibiotic resistance is remarkably thin. About Paratek ... focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds ...

Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis

... population that had significant prior inhaled antibiotic experience and many patients were infected ... many of the shortcomings of available inhaled antibiotic formulations for CF patients. These shortcomings ... -- Activity in CF sputum: Studies of antibiotic activity in CF sputum showed that ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... of the Prodrug TR-701, a Novel Oxazolidinone antibiotic -- F1-2064: Human Pharmacokinetics of TR-700 ... 200 and 400 mg of TR-701, a Novel Oxazolidinone antibiotic -- F1-2065: In Vitro and In Vivo Efficacy of ... is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant ...

Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008

... NDA or supplemental NDA. Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvox's Patient Share in the Treatment of Nosocomial Pneumonia

... in this drug market. "We presented several antibiotic product profiles to physicians we surveyed that ... Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's ... -- Hospital Anti-Infective Insight Series: U.S. antibiotic Usage Patterns and Drivers in the ICU ...

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... ill cholera patients in conjunction with an antibiotic and rehydration therapy. A double-blind ... ill cholera patients, even when receiving the antibiotic azithromycin and rehydration therapy (but ... therapy, either intravenous or oral, and antibiotic therapy to target the infectious agent. There are ...

FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia

... Response letter. DORIBAX is an intravenous (IV) antibiotic for hospital use, and belongs to a class of ... all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since ... If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to ...

Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections

... Phase 2 clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated ... in advancing this next-generation broad spectrum antibiotic further toward clinical use," said Dr. ... dosage form to meet the need for a broad-spectrum antibiotic in the hospital setting, particularly one that ...

Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections

... due to true infection, requiring aggressive antibiotic therapy, or due to blood culture contamination ... vs. 56% for UC group -- 67% reduction in median antibiotic use after notification of results; median of 1 ... 3 days for UC group -- 100% reduction in median antibiotic use for CoNS patients after notification of; 0 ...

Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients

... aerosol formulation of levofloxacin, an antibiotic that has potent activity against key bacterial ... nebulizer. Levofloxacin is a fluoroquinolone antibiotic that has been widely used in a variety ... new therapies to combat the growing issue of antibiotic resistance. The company's internal development ...

Amikacin Inhale Shows Promising Results in Phase II Study

... over 1000 times greater lung exposure to the antibiotic amikacin as compared to intravenous route of administration. This shows that targeting antibiotic therapy to the site of infection might offer ... liquid formulation of the aminoglycoside antibiotic amikacin with Nektar Therapeutics' proprietary ...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers

... gentamicin, a broad-spectrum, aminoglycoside antibiotic (having a concentration-dependent mechanism ... will be compared to an orally administered antibiotic (the current standard of care). This second phase ... investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, ...

ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

... antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of ... or new chemical entities ("NCEs"). Combination antibiotic therapy has been used as the treatment of ... "The development of an NCE for combination antibiotic treatment could be extremely beneficial," ...

FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults

... patients who present with diarrhea following antibiotic use. Careful medical history is necessary since ... If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to ... as rheumatic fever, and should be treated with antibiotic therapy. Pharyngitis ranks in the top ten ...

Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections

... found in most common infections, as well as antibiotic resistant bacteria such as ... of a novel community-based broad-spectrum antibiotic that has been designed specifically to treat MRSA ... office setting. This community-targeted oral antibiotic will be distinct from PTK 0796 and is expected to ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... Anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained normal hematologic ... abnormal hematologic parameters following antibiotic cessation. One ciprofloxacin-treated ... parameters, and died nine days after cessation of antibiotic treatments. All 10 control monkeys demonstrated a ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... Anthrax Challenge in Rhesus Macaques" All antibiotic treated animals maintained normal hematologic ... abnormal hematologic parameters following antibiotic cessation. One ciprofloxacin-treated ... parameters, and died nine days after cessation of antibiotic treatments. All 10 control monkeys demonstrated a ...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

... (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity ... candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial ...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

... and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety ... prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making ...

Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin

... under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of ...

Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009

... and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.(2) About cSSSI Complicated skin and skin structure ... allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded ...

Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories

... moderate to severe acne vulgaris, Acanya Gel is the only fixed combination antibiotic and benzoyl peroxide (BPO) medication FDA-approved for the once-daily ... Acanya Gel Acanya Gel is the only FDA-approved fixed combination antibiotic and benzoyl peroxide (BPO) medication for once-daily treatment of both ...

Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile

... combat gastrointestinal pathologies caused by C. diff. along with better antibiotic stewardship and infection control practices," said Barry Cookson, ... natural microbial flora of the gut is disturbed, usually as a result of antibiotic treatment, and a patient ingests C. difficile spores, the bacteria can ...

Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection

... bacterial bone infection--an early changeover from intravenous (IV) antibiotic delivery to oral antibiotics is just as effective as continuing the IV ... study, some 5 percent of the 1,021 children receiving the prolonged IV antibiotic had to return to the hospital for further treatment, compared to 4 percent ...